Document is current
Any future updates will be listed below
-
Authors
Ishii, Hitoshi https://orcid.org/0000-0002-6214-0557
Kamiya, Hideki https://orcid.org/0000-0003-3197-2542
Takahashi, Yoko https://orcid.org/0000-0003-2481-9574
Morimoto, Yukiko
Yabe, Daisuke https://orcid.org/0000-0002-5334-7687
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 27 August 2024
First Online: 30 September 2024
Declarations
:
: Hitoshi Ishii has received lecture fees from Novo Nordisk Pharma Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K. and Sanofi K.K. Hideki Kamiya has received lecture fees from Novo Nordisk Pharma Ltd., Sanofi K.K., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kowa Co., Ltd., Novartis Pharma K.K., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Astellas Pharma Co., Ltd.; research grants from Ono Pharmaceutical Co., Ltd., Fukuda Denshi Co., Ltd., CBC Co., Ltd., Parexel International Co., Ltd. and Kowa Co., Ltd.; and scholarship grants from Taisho Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Novo Nordisk Pharma Ltd. Yoko Takahashi and Yukiko Morimoto are employees of Sanofi K.K. (and do not hold shares/stock options in the company). Daisuke Yabe has received lecture fees from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Sanofi K.K., Kyowa Kirin Co., Ltd. and Sumitomo Pharma Co., Ltd.; research grants from Terumo Corporation and Nippon Boehringer Ingelheim Co., Ltd.; and was an endowed chair for Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co., Ltd. and ARKRAY, Inc. The present affiliation address for Daisuke Yabe is: Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
: The study was conducted in accordance with the ethical principles outlined in the 1964 Declaration of Helsinki and its subsequent revisions, the Guidelines for Good Pharmacoepidemiology Practices issued by the International Society of Pharmacoepidemiology and the Ethical Guidelines for Medical and Biological Research Involving Human Subjects issued by the Ministry of Health, Labour and Welfare of Japan. All participants provided written informed consent. Ethics committee approval for the study was granted prior to study initiation by a central ethics committee (Gifu University Hospital, Gifu, Japan; approval granted 25 January 2022).
